Axio BioPharma is a Contract Development and Manufacturing Organization (CDMO) transforming biopharmaceutical manufacturing with rapid, data-driven solutions. We accelerate the development of mammalian-expressed recombinant proteins, with a focus on monoclonal antibodies (mAbs), and offer scalable manufacturing solutions to support each stage from lab research to clinical production. Our small-scale production services range from 96-well plates to 2L volumes with a reliable 4-week turnaround—help innovators bring life-saving therapies to patients faster.